浙江东亚药业股份有限公司2025年度业绩预告

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. expects a significant net loss for the fiscal year 2025, with projected losses ranging from 75 million to 90 million yuan [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The company anticipates a net profit attributable to shareholders of the listed company to be between -90 million yuan and -75 million yuan [2][4]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between -102 million yuan and -87 million yuan [2][5]. Group 2: Previous Year Performance - In the same period last year, the total profit was -118.17 million yuan, with a net profit attributable to shareholders of -100.66 million yuan [6]. - The net profit, excluding non-recurring gains and losses, was -98.41 million yuan [6]. - The earnings per share for the previous year were -0.90 yuan per share [7]. Group 3: Reasons for Expected Loss - The primary reasons for the expected loss include: - Revenue Side: The company faced a decline in revenue due to domestic centralized procurement price reductions, industry-related policies, and intensified market competition, particularly affecting cephalosporin products [8]. - Cost Side: Increased fixed asset depreciation and bank loan interest expenses due to new projects being completed and capitalized, impacting the company's performance by approximately 32 million yuan [9]. - Asset Side: The company plans to make provisions for asset impairment, including a provision for inventory depreciation of around 35 million yuan, based on the principle of prudence and current operational conditions [10]. Group 4: Strategic Response - Despite the challenges, the company is committed to its integrated development strategy of raw materials and formulations, aiming to enhance product lines and competitiveness [10]. - The management is focused on maintaining market share, adjusting product structures, and investing in research and development to enrich the product pipeline [10].